Skadden is advising Revance Therapeutics, while Kirkland & Ellis and Lowenstein Sandler are advising Crown Laboratories on the deal. Crown Laboratories, Inc., a privately held, global...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Hildred Capital in the transaction. Hildred Capital raised $750 million for its continuation fund to extend its ownership of two of its portfolio companies, Hyland’s...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represented Crown Laboratories in the transaction. Crown Laboratories, Inc. (“Crown”), a leading, fully integrated global skincare company, announced its agreement with Eclipse MedCorp LLC,...
You must be a Standard 1 Year member to access this content.
Lowenstein advised Hildred Capital Management and Crown Laboratories on the deal, while Gibson, Dunn & Crutcher advised StriVectin and L Catterton. Hildred Capital Management (Hildred) and...
You must be a Standard 1 Year member to access this content.
Lowenstein, Beccar Varela, and Mattos Filho, Veiga Filho, Marrey Jr. E Quiroga advised Indorama Ventures on the deal. Skadden, Stocche Forbes, BMA – Barbosa, Müssnich, Aragão...
You must be a Standard 1 Year member to access this content.
Lowenstein represented Indorama Ventures in the transaction. Indorama Ventures (BKK: IVL), a global chemicals producer, completed its acquisition of CarbonLite Holdings’ facility in Texas as part of...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler represents PeriGen Inc. in the transaction. Halma plc executed the acquisition of PeriGen Inc. (PeriGen), a leading provider of perinatal health care software solutions. PeriGen’s...
You must be a Standard 1 Year member to access this content.
